Literature DB >> 29784747

New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma.

Christopher A Barker1, April K Salama1.   

Abstract

The NCCN Guidelines Panel for Melanoma debuted new guidelines for uveal melanoma at the NCCN 23rd Annual Conference. Although uveal melanoma and cutaneous melanoma share the same name, they do have different characteristics and treatments. The NCCN Guidelines describe how tumor size guides therapeutic options, which for most tumors is radiotherapy. Predictors of melanoma-related mortality include advanced age, larger tumor size, and histopathologic and molecular features. The NCCN Guidelines for Cutaneous Melanoma have not changed notably, but adjuvant therapy with immunotherapies is now recommended. The best second-line treatment in the metastatic setting remains unclear.
Copyright © 2018 by the National Comprehensive Cancer Network.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29784747     DOI: 10.6004/jnccn.2018.0042

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  12 in total

1.  Radionuclide imaging and therapy in malignant melanoma after survivin promoter-directed sodium iodide symporter gene transfer in vitro and in vivo.

Authors:  Zhen Zhao; Rui Huang; Huawei Cai; Bin Liu; Yu Zeng; Anren Kuang
Journal:  Int J Clin Exp Pathol       Date:  2019-02-01

2.  Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience.

Authors:  Vidhya Karivedu; Ihab Eldessouki; Ahmad Taftaf; Zheng Zhu; Abouelmagd Makramalla; Nagla Abdel Karim
Journal:  Case Rep Oncol Med       Date:  2019-04-17

3.  Evaluation of Racial, Ethnic, and Socioeconomic Associations With Treatment and Survival in Uveal Melanoma, 2004-2014.

Authors:  Nitya Rajeshuni; Talhah Zubair; Cassie A Ludwig; Darius M Moshfeghi; Prithvi Mruthyunjaya
Journal:  JAMA Ophthalmol       Date:  2020-08-01       Impact factor: 7.389

4.  A Novel 8-Gene Prognostic Signature for Survival Prediction of Uveal Melanoma.

Authors:  Zhongjun Tang; Kebo Cai
Journal:  Anal Cell Pathol (Amst)       Date:  2021-08-14       Impact factor: 2.916

Review 5.  Prognostic gene expression profiling in melanoma: necessary steps to incorporate into clinical practice.

Authors:  Douglas Grossman; Caroline C Kim; Rebecca I Hartman; Elizabeth Berry; Kelly C Nelson; Nwanneka Okwundu; Clara Curiel-Lewandrowski; Sancy A Leachman; Susan M Swetter
Journal:  Melanoma Manag       Date:  2019-12-17

Review 6.  Hypoxia-dependent drivers of melanoma progression.

Authors:  Simona D'Aguanno; Fabiana Mallone; Donatella Del Bufalo; Antonietta Moramarco; Marco Marenco
Journal:  J Exp Clin Cancer Res       Date:  2021-05-08

7.  Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience.

Authors:  Cornelia L A Dewald; Mia-Maria Warnke; Roland Brüning; Martin A Schneider; Peter Wohlmuth; Jan B Hinrichs; Anna Saborowski; Arndt Vogel; Frank K Wacker
Journal:  Cancers (Basel)       Date:  2021-12-27       Impact factor: 6.639

8.  Stereotactic radiosurgery with immunotherapy is associated with improved overall survival in patients with metastatic melanoma or non-small cell lung cancer: a National Cancer Database analysis.

Authors:  J M Jiang; R Kabarriti; N P Brodin; N Ohri; C Guha; S Kalnicki; M Garg
Journal:  Clin Transl Oncol       Date:  2021-07-08       Impact factor: 3.405

9.  Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma.

Authors:  Kalijn Fredrike Bol; Eva Ellebaek; Lise Hoejberg; Mette Marie Bagger; Mathilde Skaarup Larsen; Tobias Wirenfeldt Klausen; Ulrich Heide Køhler; Henrik Schmidt; Lars Bastholt; Jens Folke Kiilgaard; Marco Donia; Inge Marie Svane
Journal:  Cancers (Basel)       Date:  2019-10-03       Impact factor: 6.639

Review 10.  Current Therapeutics and Future Perspectives to Ocular Melanocytic Neoplasms in Dogs and Cats.

Authors:  Tarcísio Guerra Guimarães; Karla Menezes Cardoso; Pedro Tralhão; Carlos Miguel Marto; Nuno Alexandre; Maria Filomena Botelho; Mafalda Laranjo
Journal:  Bioengineering (Basel)       Date:  2021-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.